Stanley Madu Nwabudike

Stanley Madu Nwabudike

Auto-generated profile, based on publicly available information

Stanley Madu Nwabudike

Boston Medical Center, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2016 in Case Reports in Infectious Diseases
Verified
Journal Article
Open access
PDF file
SNStanley M. Nwabudike
Stanley M. Nwabudike
SHStefan Hemmings
Stefan Hemmings
YPYonette Paul
Yonette Paul
YHYordanis Habtegebriel
Yordanis Habtegebriel
OPOctavius Polk
Octavius Polk
AMAlem Mehari
Alem Mehari
Kaposi Sarcoma (KS) is the most common malignancy associated with Acquired Immune Deficiency Syndrome (AIDS) and is caused by Human Herpesvirus 8 (HHV 8) or Kaposi Sarcoma Herpesvirus (KSHV). In about 90% of cases Kaposi Sarcoma is associated with cutaneous lesions; however visceral disease can occur in the absence of cutaneous involvement. In the era of Highly Active Antiretroviral Therapy (HAART), the incidence of KS has declined. Clinical features of pulmonary KS might be difficult to distinguish from pneumonia in the immunocompromised patients and could lead to diagnostic challenges. First-line treatment of KS is with HAART and the incidence has declined with its use. Systemic chemotherapy may play a role depending on the extent of the disease. We report the case of a young man who presented with pulmonary symptoms and was later found to have pulmonary KS. Interestingly this diagnosis was made in the absence of the classic skin lesions. His disease was complicated by progressive respiratory failure and he eventually died.

1 December 2019 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
OAOladimeji Akinboro
Oladimeji Akinboro
SNStanley Madu Nwabudike
Stanley Madu Nwabudike
RERawad Elias
Rawad Elias
OBOluseyi Balasire
Oluseyi Balasire
OOOlatunde Ola
Olatunde Ola
JOJamie S. Ostroff
Jamie S. Ostroff
Background: The prevalence of electronic cigarette (e-cigarette) use and its impact on smoking cessation among cancer survivors in the United States is largely unknown. We sought to estimate the prevalence of e-cigarette use and examine its associations with cigarette smoking and smoking quit attempts among smoking-related cancer survivors in the United States. Methods: We obtained data from the 2014–2017 annual cycles of the National Health Interview Survey for participants with self-reported history of smoking-related cancer(s). We calculated the prevalence of current e-cigarette use and utilized multinomial logistic regression in examining the independent association between e-cigarette use and cigarette smoking. Appropriate survey weights were applied in estimating the prevalence rates, relative risk ratios (RRR), ORs, and confidence intervals (CI). Results: Our sample comprised 3,162 smoking-related cancer survivors. The prevalence of current e-cigarette use was 3.18% (95% CI, 2.40–3.96). Current e-cigarette users were 83 times as likely as never users to be current cigarette smokers (RRR, 82.89; 95% CI, 16.54–415.37). Among those with a history of cigarette smoking, current e-cigarette users were 90% less likely to be former smokers (OR, 0.10; 95% CI, 0.05–0.18). No association was seen between current e-cigarette use and a smoking quit attempt in the prior year. Conclusions: E-cigarette use among cigarette ever smokers was associated with a lower likelihood of being a former smoker/having quit smoking, and e-cigarette use was not associated with smoking quit attempts. Impact: Our findings do not provide evidence that e-cigarette use facilitates smoking cessation among smoking-related cancer survivors.

2 June 2015 in Case Reports in Hematology
Verified
Journal Article
Open access
PDF file
SYSri Lakshmi Hyndavi Yeruva
Sri Lakshmi Hyndavi Yeruva
SNStanley Madu Nwabudike
Stanley Madu Nwabudike
OOOnyekachi Henry Ogbonna
Onyekachi Henry Ogbonna
POPatricia Oneal
Patricia Oneal
Aromatase inhibitors (AIs) are most commonly used for breast cancer patients with hormone receptor positive disease. Although the side effect profile of aromatase inhibitors is well known, including common side effects like arthralgia, bone pain, arthritis, hot flashes, and more serious problems like osteoporosis, we present a case of an uncommon side effect of these medications. We report the case of a postmenopausal woman on adjuvant hormonal therapy with anastrozole after completing definitive therapy for stage IIIB estrogen receptor-positive breast cancer, who was referred to hematology service for evaluation of persistent erythrocytosis. Primary and known secondary causes of polycythemia were ruled out. On further evaluation, we found that her erythrocytosis began after initiation of anastrozole and resolved after it was discontinued. We discuss the pathophysiology of aromatase inhibitor-induced erythrocytosis and reference of similar cases reported in the literature.

24 June 2016 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
AAAhmed Ali
Ahmed Ali
YPYonette Paul
Yonette Paul
SNStanley Madu Nwabudike
Stanley Madu Nwabudike
OOOnyekachi Ogbonna
Onyekachi Ogbonna
MGMica Grantham
Mica Grantham
LTLekidelu Taddesse-Heath
Lekidelu Taddesse-Heath
Plasma cell leukemia (PCL) is an uncommon neoplasm of plasma cells, with an aggressive clinical course and poor outcome, even with current standard of care. It can occur either de novo (primary PCL) or as a progression of multiple myeloma (MM). This disease has unique diagnostic criteria but certain genetic markers and clinical features may overlap with MM. Due to the low prevalence of PCL, guidelines on its management are extrapolated from the management of MM and based on small retrospective studies and cases reports/series. We present an interesting case of PCL in a middle-aged African-American male, who was diagnosed incidentally after chest wall imaging for an unrelated complaint. The diagnostic approach, management and outcomes of PCL are discussed.

13 December 2018 in Case Reports in Hematology
Verified
Journal Article
Open access
PDF file
SNStanley Madu Nwabudike
Stanley Madu Nwabudike
CECamille V. Edwards
Camille V. Edwards
OAOladimeji Akinboro
Oladimeji Akinboro
KQKathryn Quinn
Kathryn Quinn
SSShayna Sarosiek
Shayna Sarosiek
NKNaomi Ko
Naomi Ko
Breast cancer is the most common cancer diagnosed in women worldwide. Over the years, breast cancer treatment has undergone revolutionary changes especially for women with hormone receptor positive metastatic disease. As a result, women are living longer with their disease, particularly in developed countries. The use of cyclin-dependent kinase (CDK) 4/6 inhibitors with antiestrogen therapy is a relatively new therapeutic option which has been shown to improve progression-free survival. Hematologic adverse events, most frequently neutropenia, are well-known side effects of CDK 4/6 inhibitors. However, to our knowledge, aplastic anemia has never been reported. We report a case of aplastic anemia in a patient with metastatic breast cancer treated with palbociclib after multiple prior lines of therapy.